Gapping up
In reaction to earnings/guidance:
- ACCD +10.9%, NARI +6.8%, SONX +6.6%, BBW +6%, ANF +5.9%, BARK +5% (also names new CEO), VECO +5%, ILMN +4.6% (also announces multiple new partnerships), PI +4.4%, CRL +2.2%, SLGC +1.9%, OCDX +1.7%, DHR +1.6%, CVS +1.4%, DLTH +0.8%, NOK +0.6%
Other news:
- BDTX +19.6% (FDA allowance of IND Application for BDTX-1535 a masterkey inhibitor of EGFR for the treatment of gliobastoma and non-small cell lung cancer)
- VIR +8.6% (Vir Biotechnology and GlaxoSmithKline plc (GSK) announce that the US government will purchase an additional 600000 doses of sotrovimab enabling further nationwide access to sotrovimab for patients)
- QSI +7.7% (provides commercial update)
- BLUE +7.3% (provides updates on FDA reviews and assets for FY22 ahead of JP Morgan Healthcare conference)
- FREY +4.1% (FREYR Battery and Aleees to pursue LFP cathode manufacturing joint venture)
- ZY +3.9% (Debuts Automation Business and Shares Program Portfolio at 40th Annual JP Morgan Healthcare Conference)
- VLDR +3.6% (announced a five-year sales agreement for its lidar sensors with QinetiQ )
- BCAB +3% (BCAB announces clinical collaboration with BMY)
- VSTM +2.6% (outlines key strategic priorities and upcoming catalysts to support its lead compound VS-6766 in 2022)
- EXK +2.3% (Q4 production)
- EPAM +1.7% (EPAM Continuum appointed strategic digital partner for launch of INEOS Automotive's new Grenadier Vehicle)
- STAG +1.6% (names new CEO effective July 1; also names new CFO)
- INTC +1.1% (names new CFO comes over from Micron)
Analyst comments:
- JNPR +4.5% (upgraded to Buy from Underperform at BofA Securities)
- AAL +2.2% (upgraded to Equal-Weight from Underweight at Morgan Stanley)
- ATI +2% (upgraded to Outperform from Market Perform at Cowen)
- CERT +1.9% (upgraded to Buy from Hold at Jefferies )
- AMD +1.6% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)